Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Reports Increased Revenues, Widened Loss in Q4; Eyes Profitability in Q4 02

NEW YORK, Jan. 30 - Transgenomic on Wednesday said that its fourth-quarter losses widened as increased sales of its gene analysis equipment and chemicals failed to counter a jump in operating expenses.

Revenue swelled 51 percent to $10.7 million from $7.1 million one year ago, the company said.

Net loss for the period ended Dec. 31 widened to $2.7 million, or 12 cents a share, from $374,000, or 2 cents a share, year over year. 
 

Transgenomic also posted a 62 percent hike in revenues for fiscal 2001 to $38.5 million from $23.7 million in 2000. The firm also posted a net loss $7.4 million, or $0.33 per share, in fiscal 2001, compared with a loss of $8.6 million, or $0.52 per share, in 2000.

"We expect our total revenues to increase in the range of 45 percent to 55 percent this year," said Greg Duman, Transgenomic's chief financial officer. "The growing synthetic nucleic acids business is a significant component in meeting the company's overall revenue growth targets for 2002.

 

"Our 2002 plans project profitability in the fourth quarter of this year," he added.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.